OBJECTIVE: To investigate differences in subclinical coronary atherosclerotic plaque and markers of immune activation among HIV-infected and non-HIV-infected women categorized by degree of ovarian reserve and menopause status. DESIGN: Cross-sectional evaluation. METHODS: Seventy-four women (49 HIV-infected, 25 non-HIV-infected) without known cardiovascular disease (CVD) were classified as premenopausal, premenopausal with reduced ovarian reserve, or postmenopausal based on menstrual history and anti-Müllerian hormone (AMH) levels. Participants underwent contrast-enhanced coronary computed tomography angiography and immune phenotyping. Comparisons in coronary atherosclerotic plaque burden and immune markers were made between the HIV-infected and non-HIV-infected women overall and within the HIV-infected and non-HIV-infected women by reproductive classification group. RESULTS: Among the overall group of HIV-infected women, the women with reduced ovarian reserve (undetectable AMH) had a higher prevalence of coronary atherosclerotic plaque (52 versus 6%, P = 0.0007) and noncalcified plaque (48 versus 6%, P = 0.002), as well as higher levels of log sCD163 (P = 0.0004) and log MCP-1 (P = 0.006), compared with the premenopausal women with measurable AMH. Furthermore, reduced ovarian reserve in the HIV-infected group related to noncalcified plaque, controlling for traditional CVD risk factors (P = 0.04) and sCD163 (P = 0.03). CONCLUSION: HIV-infected women with reduced ovarian reserve have increased subclinical coronary atherosclerotic plaque compared with premenopausal women in whom AMH is measurable. This relationship holds when controlling for CVD risk factors (including age) and immune activation. Our findings demonstrate that reduced ovarian reserve may contribute to CVD burden in HIV-infected women and support a comprehensive assessment of CVD risk prior to completion of menopause in this population.
OBJECTIVE: To investigate differences in subclinical coronary atherosclerotic plaque and markers of immune activation among HIV-infected and non-HIV-infectedwomen categorized by degree of ovarian reserve and menopause status. DESIGN: Cross-sectional evaluation. METHODS: Seventy-four women (49 HIV-infected, 25 non-HIV-infected) without known cardiovascular disease (CVD) were classified as premenopausal, premenopausal with reduced ovarian reserve, or postmenopausal based on menstrual history and anti-Müllerian hormone (AMH) levels. Participants underwent contrast-enhanced coronary computed tomography angiography and immune phenotyping. Comparisons in coronary atherosclerotic plaque burden and immune markers were made between the HIV-infected and non-HIV-infectedwomen overall and within the HIV-infected and non-HIV-infectedwomen by reproductive classification group. RESULTS: Among the overall group of HIV-infectedwomen, the women with reduced ovarian reserve (undetectable AMH) had a higher prevalence of coronary atherosclerotic plaque (52 versus 6%, P = 0.0007) and noncalcified plaque (48 versus 6%, P = 0.002), as well as higher levels of log sCD163 (P = 0.0004) and log MCP-1 (P = 0.006), compared with the premenopausal women with measurable AMH. Furthermore, reduced ovarian reserve in the HIV-infected group related to noncalcified plaque, controlling for traditional CVD risk factors (P = 0.04) and sCD163 (P = 0.03). CONCLUSION:HIV-infectedwomen with reduced ovarian reserve have increased subclinical coronary atherosclerotic plaque compared with premenopausal women in whom AMH is measurable. This relationship holds when controlling for CVD risk factors (including age) and immune activation. Our findings demonstrate that reduced ovarian reserve may contribute to CVD burden in HIV-infectedwomen and support a comprehensive assessment of CVD risk prior to completion of menopause in this population.
Authors: R A Clark; K Mulligan; E Stamenovic; B Chang; H Watts; J Andersen; K Squires; C Benson Journal: J Infect Dis Date: 2001-10-02 Impact factor: 5.226
Authors: Shenghan Lai; Joao A C Lima; Hong Lai; David Vlahov; David Celentano; Wenjing Tong; John G Bartlett; Joseph Margolick; Elliot K Fishman Journal: Arch Intern Med Date: 2005-03-28
Authors: Helen S Kok; Kristel M van Asselt; Yvonne T van der Schouw; Ingeborg van der Tweel; Petra H M Peeters; Peter W F Wilson; Peter L Pearson; Diederick E Grobbee Journal: J Am Coll Cardiol Date: 2006-04-24 Impact factor: 24.094
Authors: Leslee J Shaw; C Noel Bairey Merz; Carl J Pepine; Steven E Reis; Vera Bittner; Sheryl F Kelsey; Marian Olson; B Delia Johnson; Sunil Mankad; Barry L Sharaf; William J Rogers; Timothy R Wessel; Christopher B Arant; Gerald M Pohost; Amir Lerman; Arshed A Quyyumi; George Sopko Journal: J Am Coll Cardiol Date: 2006-02-07 Impact factor: 24.094
Authors: Leah H Rubin; Gayle Springer; Eileen M Martin; Eric C Seaberg; Ned C Sacktor; Andrew Levine; Victor G Valcour; Mary A Young; James T Becker; Pauline M Maki Journal: J Acquir Immune Defic Syndr Date: 2019-07-01 Impact factor: 3.731
Authors: Mabel Toribio; Tomas G Neilan; Magid Awadalla; Lauren A Stone; Adam Rokicki; Corinne Rivard; Connor P Mulligan; Diana Cagliero; Lindsay T Fourman; Takara L Stanley; Jennifer E Ho; Virginia A Triant; Tricia H Burdo; Michael D Nelson; Lidia S Szczepaniak; Markella V Zanni Journal: J Clin Endocrinol Metab Date: 2019-12-01 Impact factor: 5.958
Authors: Jyoti S Mathad; Nikhil Gupte; Ashwin Balagopal; David Asmuth; James Hakim; Breno Santos; Cynthia Riviere; Mina Hosseinipour; Patcharaphan Sugandhavesa; Rosa Infante; Sandy Pillay; Sandra W Cardoso; Noluthando Mwelase; Jyoti Pawar; Sima Berendes; Nagalingeswaran Kumarasamy; Bruno B Andrade; Thomas B Campbell; Judith S Currier; Susan E Cohn; Amita Gupta Journal: J Acquir Immune Defic Syndr Date: 2016-10-01 Impact factor: 3.731
Authors: Kathleen V Fitch; Christopher DeFilippi; Robert Christenson; Suman Srinivasa; Hang Lee; Janet Lo; Michael T Lu; Kimberly Wong; Eva Petrow; Laura Sanchez; Sara E Looby; Udo Hoffmann; Markella Zanni; Steven K Grinspoon Journal: AIDS Date: 2016-09-10 Impact factor: 4.177
Authors: Felicia C Chow; Susan Regan; Markella V Zanni; Sara E Looby; Cheryl D Bushnell; James B Meigs; Steven K Grinspoon; Steve K Feske; Virginia A Triant Journal: AIDS Date: 2018-01-02 Impact factor: 4.177